Insider Selling: Insulet Co. (NASDAQ:PODD) Director Sells $1,333,570.00 in Stock

Insulet Co. (NASDAQ:PODDGet Free Report) Director Timothy J. Scannell sold 7,000 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $190.51, for a total value of $1,333,570.00. Following the sale, the director now directly owns 35,586 shares in the company, valued at $6,779,488.86. The sale was disclosed in a filing with the SEC, which is available through this link.

Insulet Stock Up 0.6 %

Shares of PODD opened at $201.84 on Friday. The firm has a fifty day moving average price of $176.97 and a 200-day moving average price of $185.73. The company has a current ratio of 3.74, a quick ratio of 2.75 and a debt-to-equity ratio of 1.72. The firm has a market capitalization of $14.14 billion, a P/E ratio of 61.16, a P/E/G ratio of 3.46 and a beta of 1.14. Insulet Co. has a 12-month low of $125.82 and a 12-month high of $298.95.

Insulet (NASDAQ:PODDGet Free Report) last issued its earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.34. The business had revenue of $441.70 million for the quarter, compared to the consensus estimate of $424.05 million. Insulet had a net margin of 13.14% and a return on equity of 34.06%. The company’s revenue for the quarter was up 23.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.23 EPS. Equities research analysts expect that Insulet Co. will post 3.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on PODD. Jefferies Financial Group upped their price target on shares of Insulet from $255.00 to $260.00 and gave the company a “buy” rating in a research note on Friday, May 10th. Raymond James decreased their target price on shares of Insulet from $218.00 to $213.00 and set an “outperform” rating on the stock in a research report on Friday, May 10th. Piper Sandler dropped their price target on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research report on Friday, February 23rd. Barclays decreased their price objective on Insulet from $213.00 to $200.00 and set an “equal weight” rating on the stock in a research report on Monday, May 13th. Finally, Wolfe Research upgraded Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 target price for the company in a report on Tuesday, May 7th. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, Insulet currently has an average rating of “Moderate Buy” and a consensus price target of $239.18.

Read Our Latest Analysis on PODD

Institutional Investors Weigh In On Insulet

Several hedge funds have recently made changes to their positions in PODD. Wolff Wiese Magana LLC raised its holdings in shares of Insulet by 2,680.0% in the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 134 shares in the last quarter. Benjamin F. Edwards & Company Inc. bought a new stake in shares of Insulet in the 4th quarter valued at about $34,000. Sunbelt Securities Inc. purchased a new stake in shares of Insulet in the 1st quarter worth approximately $29,000. Parkside Financial Bank & Trust boosted its stake in shares of Insulet by 251.0% during the third quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 123 shares in the last quarter. Finally, Jones Financial Companies Lllp purchased a new position in Insulet during the fourth quarter valued at approximately $40,000.

About Insulet

(Get Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Read More

Insider Buying and Selling by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with's FREE daily email newsletter.